UBS Maintains Neutral on Teva Pharmaceutical Indus, Raises Price Target to $11
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Ashwani Verma maintains a Neutral rating on Teva Pharmaceutical Indus (NYSE:TEVA) and raises the price target from $8 to $11.
September 20, 2023 | 1:08 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
UBS analyst Ashwani Verma maintains a Neutral rating on Teva Pharmaceutical Indus and raises the price target from $8 to $11.
The news is directly about Teva Pharmaceutical Indus. UBS analyst Ashwani Verma maintains a Neutral rating on the company, indicating no significant changes are expected in the short term. However, the increase in price target from $8 to $11 suggests a positive outlook in the longer term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100